Physician profile
Mehri Songhorian
NPI 1407838766
$7,817.42
in general payments reported to CMS, 2019-2025
24 companies · $745 in 2025
The $745 reported for 2025 was more than what 83% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $540 · 2021: $1,307 · 2022: $1,500 · 2023: $1,383 · 2024: $1,494 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603 · Education: $18.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,602.97 |
| Education | $18.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $1,655.46 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,187.47 | 2020-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $1,126.16 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Teva Pharmaceuticals USA, INC. | $895.44 | 2021-2024 | Austedo, Austedo Xr |
| Neurelis, INC. | $420.70 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $398.42 | 2022-2024 | Xcopri |
| Sunovion Pharmaceuticals INC. | $372.42 | 2019-2022 | |
| Abbott Laboratories | $314.46 | 2023-2025 | Freestyle Libre 3, Infinity |
| Sumitomo Pharma America, INC. | $196.54 | 2023-2024 | Aptiom |
| Jazz Pharmaceuticals INC. | $176.89 | 2022-2024 | |
| Amgen INC. | $149.96 | 2019 | |
| Progenics Pharmaceuticals, INC. | $125.00 | 2023 | Pylarify |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2022 | |
| Ucb, INC. | $115.31 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $106.39 | 2023-2024 | Ztlido |
| Biogen, INC. | $77.19 | 2021 | |
| Lilly USA, LLC | $67.03 | 2022-2023 | Amyvid |
| Allergan, INC. | $66.72 | 2020 | |
| Medtronic, INC. | $38.75 | 2024 | Percept Pc Brainsense |
| E.R. Squibb & Sons, L.L.C. | $23.08 | 2024 | Cobenfy |
| Novartis Pharmaceuticals Corporation | $20.78 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $16.72 | 2024 | |
| Aprecia Pharmaceuticals, LLC | $16.53 | 2023 | Spritam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mehri Songhorian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.